SION
Sionna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.18
+6.37%Aug 16, 2026, 22:00 UTC
SBS Law announced an investigation into potential securities fraud claims on behalf of Sionna Therapeutics, Inc. investors.
Aug 13, 2026, 02:03 UTC
Robbins Geller Rudman & Dowd LLP announced an investigation into Sionna Therapeutics, Inc. for potential violations of U.S. federal securities laws.
Source:Aug 10, 2026, 12:03 UTC
Sionna Therapeutics announced that its experimental cystic fibrosis pill SION-719 failed to show benefit in a Phase 2 trial when added to Vertex Pharmaceuticals' Trikafta, and the company will not advance it as an add-on therapy.
Aug 10, 2026, 11:13 UTC
SIONNA Therapeutics' stock plunged 87% in pre-market trading after the company released updated data on its primary endpoint.
Aug 6, 2026, 11:00 UTC
Sionna Therapeutics reported its financial results for the second quarter of 2026.
Source: